Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N C TURNER

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
ESMO Open|September 6, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 studyH S Rugo, M Oliveira, S J Howell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2019
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-populationN C Turner, E Alarcón, A C Armstrong, et al.
Nature Communications|November 5, 2024
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancerM T Herrera-Abreu, J Guan, U Khalid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 24, 2022
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancerN C Turner, C Swift, B Jenkins, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
ESMO Open|September 6, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 studyH S Rugo, M Oliveira, S J Howell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2019
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-populationN C Turner, E Alarcón, A C Armstrong, et al.
Nature Communications|November 5, 2024
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancerM T Herrera-Abreu, J Guan, U Khalid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 24, 2022
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancerN C Turner, C Swift, B Jenkins, et al.
Pageof 7